Escalating global mental health crisis, growing unmet mental health needs, increasing regulatory agencies' support, growing healthcare investments, and expanding R&D activities are promoting the market growth.
Market Snapshot: The Rise of Psychedelic Drugs in the U.S.
The psychedelic drugs refer to a class of psychoactive substances utilized to alter thought, perception, mood, and sense of reality. These products help in the treatment of various mental health disorders, where it helps in enhancing emotional processing, chronic trauma, and overcome additions. These drugs are used for the treatment of mental health disorders, psychotherapy assistance, neuroscience research, and recreational use.
Global Market Growth
The global psychedelic drugs market size was estimated at USD 5.82 billion in 2025 and is predicted to increase from USD 6.68 billion in 2026 to approximately USD 23.14 billion by 2035, expanding at a CAGR of 14.8% from 2026 to 2035
Rewiring Psychiatry: Unlocking Opportunities in Psychedelic Drugs
- Increasing mental health disorders across the U.S. are increasing the demand for their treatment options, which is increasing the adoption of psychedelic drugs.
- Growing government support and FDA fast-track approvals are also encouraging their innovations.
- Expanding healthcare programs are also increasing their demand, as well as promoting the development of personalized medications.
- Increasing R&D investments and funding are also driving the psychedelic drugs advancements.
- Expanding use of psilocybin-based therapies, non-hallucinogenic psychedelic drugs are also creating new opportunities.
- Increasing focus on addiction treatment and digital mental health platforms is also fueling their innovations.
The graph represents a comparison between the U.S. adults affected with OCD (Obsessive-Compulsive Disorder), GAD (Generalized Anxiety Disorder), and PTSD (Post-Traumatic Stress Disorder). It indicates that there will be a rise in mental health disorders, which will drive the demand for safe and effective treatment options. This, in turn, will increase the adoption of psychedelic drugs for the effective management and treatment of various mental health disorders, which will ultimately promote the market growth.
Market Segmentation Overview
- By drug type, the psilocybin segment accounted for the highest revenue share of 34% of the U.S. psychedelic drugs market in 2025 and is expected to witness the fastest growth with a CAGR during the forecast period, due to their strong clinical evidence. Their natural origin and enhanced safety also increased their use. Growth in the clinical trials also increased their demand.
- By application type, the depression segment held a major revenue share of 38% of the U.S. psychedelic drugs market in 2025, driven by growth in its incidence rates. A rise in the treatment resistance associated with antidepressants increased the adoption of psychedelic drugs. Their faster and longer-lasting effects also increased their use.
- By route of administration type, the oral segment contributed the biggest revenue share of 46% of the U.S. psychedelic drugs market in 2025, due to its easy and non-invasive approach. Their accurate dosing also increased the patient acceptance rates. Their easy manufacturing and enhanced scalability also increased their adoption rates and innovations.
- By end user, the hospitals segment held the largest revenue share of 31% of the U.S. psychedelic drugs market in 2025, due to the presence of medical supervisors, which increased their acceptance rates. Enhanced safety, risk management, and structured treatment protocols also increased their preference. The presence of reimbursement policies and emergency care interventions also increased their use.
- By treatment model type, the psychedelic-assisted therapy segment led the U.S. psychedelic drugs market with 58% share in 2025, due to their enhanced effect with combination with psychotherapy. Their strong clinical outcomes also increased their use. Moreover, their higher effectiveness and reduced psychological risk also increased their demand.
Regional Analysis
The U.S. psychedelic drugs market held 33% share in 2025 and is expected to show significant growth during the forecast period, due to the presence of a robust clinical research ecosystem. Growth in mental health disorders and veteran mental health programs also increased the adoption of psychedelic drugs. The presence of robust companies also contributed to the development of new products, which were supported by investments from various sources, which enhanced the market growth.
Psychedelic Powerhouses: U.S. Top Companies Driving Psychedelic Innovations
Compass Pathways dominated the market with its Psilocybin product, where AtaiBeckley was its closest contender, which offered 5-MeO-DMT and arketamine. Definium Therapeutics also sustained its position by offering LSD-based compounds, where Helus Pharma also contributed to the market growth with its Deuterated psilocin analog and short-acting DMT compounds.
Segments Covered in the Report
By Drug Type
- Psilocybin
- Synthetic Psilocybin
- Natural Mushroom-Derived Psilocybin
- Ketamine & Esketamine
- Racemic Ketamine
- Esketamine Nasal Spray
- MDMA
- Prescription MDMA
- Combination-Assisted MDMA Therapy
- LSD
- Microdose LSD
- Full-Dose LSD Therapeutics
- DMT
- Ayahuasca-Based DMT
- Synthetic DMT
- Others
- Ibogaine
- Mescaline
- Novel Psychedelic Analogs
By Application
- Depression
- Treatment-Resistant Depression
- Major Depressive Disorder
- Postpartum Depression
- Post-Traumatic Stress Disorder (PTSD)
- Anxiety Disorders
- Generalized Anxiety Disorder
- End-of-Life Anxiety
- Substance Use Disorders
- Alcohol Use Disorder
- Opioid Use Disorder
- Nicotine Addiction
- Bipolar Disorder
- Chronic Pain & Neurological Disorders
- Others
- Eating Disorders
- OCD
- Cluster Headaches
By Route of Administration
- Oral
- Capsules
- Tablets
- Oral Films
- Nasal
- Injectable
- Intravenous
- Intramuscular
- Sublingual/Buccal
- Others
By End User
- Hospitals
- Psychiatric Clinics
- Rehabilitation Centers
- Specialty Psychedelic Therapy Centers
- Research Institutes
By Treatment Model
- Psychedelic-Assisted Therapy
- Standalone Pharmacotherapy
- Integrated Digital Therapeutics & Monitoring
By Molecule Source
- Synthetic
- Natural/Botanical
- Semi-Synthetic
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics & Therapy Centers
